In the course of ensuring the currency of published information, Swissmedic has made editorial and content-related clarifications in the guidance document Authorisation of human medicinal product with known active substance HMV4 which reflect Swissmedic practice and do not involve any new requirements for applicants. In particular, references to international guidelines have been updated.
The revised guidance document is valid with effect from 1 June 2022.